According to officials, three workers of a city-based pharmaceutical company Marion Biotech whose cough syrup is thought to have killed 18 children in Uzbekistan last year were detained on suspicion of producing and dispensing contaminated medicines. Following the filing of a FIR late Thursday night against five Marion Biotech employees, including two of its directors, in response to a complaint by a drugs inspector with the Central Drugs Standard Control Organization (CDSCO), the arrests were made. According to police, the directors are still at large and an investigation is ongoing to find them.
According to the drug inspector who filed the complaint, the Central and Uttar Pradesh drug authorities had examined samples of Marion Biotech goods and discovered 22 of them to be “not of standard quality” (adulterated and fake). “Three people connected to Marion Biotech, which is based in Sector 67, were today detained by officers from the neighborhood’s Phase 3 police station. These individuals prepared and sold phony medications that seriously harmed the general public “Rajiv Dixit, additional deputy commissioner of police for Central Noida, stated.
“In addition to the three suspects who have already been detained, searches are currently being conducted for two further firm directors, and they will shortly be detained as well. These individuals were putting human life and health at peril by their actions “said Dixit. The officer further stated that a thorough legal investigation into the incident will be conducted. In-charge of Phase 3 police station According to Vijay Kumar, the three people detained have been identified as analytical chemist Mool Singh, production chemist Atul Rawat, and head of operations Tuhin Bhattacharya. Jaya Jain and Sachin Jain are the company’s missing directors who have been apprehended, according to Kumar.
Sections 274 (adulteration of drugs), 275 (sale of adulterated drugs), and 276 (sale of drug as a different drug or medical preparation) of the Indian Penal Code, as well as Section 17 (misbranded drugs) and related violations of the 1940 Drugs and Cosmetics Act, were the legal bases for the filing of the FIR. The CDSCO opened an investigation after Marion Biotech came under fire in December of last year for its cough medicine Dok-1, which is thought to have killed 18 children who ingested it in Uzbekistan. After inspections at its facility by the central and state drug authorities in the wake of the incident, the company’s production license was suspended in January.
A “medical product alert” was issued by the World Health Organization (WHO) on January 12 in reference to two subpar (infected) items that were discovered in Uzbekistan and reported to it on December 22, 2022. “AMBRONOL syrup and DOK-1 Max syrup are the two items. MARION BIOTECH PVT. LTD is listed as the product’s manufacturer for both items (Uttar Pradesh, India). The mentioned manufacturer has not yet given WHO assurances regarding the security and caliber of these products “then, the WHO had remarked. “National quality control laboratories of the Ministry of Health of the Republic of Uzbekistan conducted laboratory analysis of samples of both goods and determined both items had excessive quantities of diethylene glycol and/or ethylene glycol as contaminants,” it had added.
More About Marion Biotech
Marion Biotech is Emenox Group’s flagship firm. It is a professionally managed, dynamic Health Care Business committed to providing the best Pharmaceuticals, Nutraceuticals, Herbals, and Cosmetic products through continuous R&D. Marion Biotech strongly believes in an integrated approach to health care, and we set high quality, safety, and efficacy criteria for all of the products we create. The items are established category leaders and household names in Central Asian countries, Central and Southern America, South East Asia, and Africa. Marion Biotech has an ultramodern production facility in Noida, India (UP). Marion Biotech’s manufacturing facility is outfitted with cutting-edge technology and staffed by highly skilled and trained technologists.
About Publisher
IR Research Publication is Publisher, Editorial, and Profile Building Service Provider. It Covers the Publication of Multiple Reputed Journals in the field of Biological, Medical, Pharmaceutical, and Life Sciences. IR Research Publication provides news on CDSCO decisions and FDA decisions, pharmaceutical industries, generic drugs, patents, and other pharma news.
For more details visit the link- https://irrespub.com/
